Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Prevalence and risk factors of prolonged QT interval and electrocardiographic abnormalities in persons living with HIV

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Effectiveness and safety of IFN-free DAA HCV therapy in HIV/HCV co-infected persons: Results from a pan-European study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. How to RESPOND to Modern Challenges for People Living with HIV: A Profile for a New Cohort Consortium

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • European Treatment Network for HIV, Hepatitis and Global Infectious Diseases (NEAT-ID) Consensus Panel
  • Lars Peters
Vis graf over relationer

: In response to growing evidence of an expanding epidemic of sexually acquired hepatitis C virus (HCV) infection in HIV-positive MSM, the European AIDS Treatment Network (NEAT) acute hepatitis C consensus panel developed their first recommendations for HCV prevention and care during a consensus conference in May 2010 in Paris, France. As then, two major breakthroughs have changed the landscape. First, directly acting antivirals (DAA) with high levels of tolerability and HCV cure rates of over 95% are now widely available and will play a large role in the goal of elimination of HCV by 2030 (WHO sector strategy). Second, landmark studies demonstrated that universal test and treatment (UTT) approach as well as the demonstration that HIV cannot be sexually transmitted from a person living with HIV with an undetectable viraemia [undetectable = untransmittable (U = U) campaign] and HIV preexposure prophylaxis (PrEP) are very effective HIV biomedical prevention strategies for MSM. The scale-up of these interventions has reduced HIV incidence in MSM and also changed patterns of sexual networks and behaviour, which has contributed to increased HCV incidence among HIV-negative MSM who were eligible for or on PrEP. These recent developments, together with new clinical and scientific insights, underscore the importance of updating the statements and recommendations for acute HCV in both HIV-positive and HIV-negative MSM. In June 2019, experts from different disciplines and organizations including community representatives participated at the second acute HCV consensus conference of NEAT Infectious Diseases (ID) in Amsterdam, the Netherlands.

OriginalsprogEngelsk
TidsskriftAIDS
Vol/bind34
Udgave nummer12
Sider (fra-til)1699-1711
Antal sider13
ISSN0269-9370
DOI
StatusUdgivet - 1 okt. 2020

ID: 61229669